Pfizer completes acquisition of ADHD drugmaker, NextWave Pharmaceuticals

Hannah Blake


Pfizer has completed its acquisition of NextWave Pharmaceuticals, following the announcement it was to purchase the company in a deal worth as much as US $700 million back in October.

NextWave Pharmaceuticals is a company solely focused on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD).

Upon closing of this transaction, Pfizer now holds the exclusive North American commercialization rights to Quillivant XR (methylphenidate hydrochloride) for extended-release oral suspension, CII, the first once-daily liquid medication approved in the US for the treatment of ADHD. Quillivant XR received approval from the US Food and Drug Administration (FDA) in September 2012.

Pfizer expects Quillivant XR to be available in US pharmacies in January 2013.




Related news:

Pfizer completes acquisition of NextWave Pharma (Bloomberg Businessweek)

Reference links:

Pfizer official press release

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.